Ｐａｇｅ 4026 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼FDA Updates name fo MypeCannope 08/7/24(木) 5:34 ─────────────────────────────────────── ■題名 ： FDA Updates name fo ■名前 ： MypeCannope <rhsfsfrre@googlemail.com> ■日付 ： 08/7/24(木) 5:34 ■Ｗｅｂ ： http://google.com -------------------------------------------------------------------------
| ROCKVILLE, Md., July 14, 2008--Genentech, Inc. alert to healthcare professionals of blasts of divers cases of microangiopathic hemolytic anemia (MAHA) in patients with concrete tumors receiving Avastin in solution with sunitinib malate. Avastin is not approved for use in solution with sunitinib malate and this party is not recommended. Twenty-five patients were enrolled in a time I dosage-escalation exawmination combining Avastin and sunitinib malate. The examination consisted of 3 cohorts using a regular portion of Avastin at 10mg/kg/IV every 2 weeks and escalating portions of sunitinib that listd 25, 37.5, and 50 mg orally quotidian premised in a 4 weeks on/ 2 weeks off scheduel. Five of 12 patients at the highest sunitinib portion plain exhibited laboratory findings undeviating with MAHA. Two of these cases were considered sober with show of thrombocytopenia, anemia, reticulocytosis, reductions in serum haptoglobin, schistocytes on circumferential defile, sensible increases in serum creatinine planes, and sober hypertension, reversible latter leukoencephalopathy syndrome, and proteinuria. The findings in these two cases were reversible within three weeks upon discontinuation of both drugs without additional interventions. Healthcare professionals should story cases of MAHA or any dangerous adverse events suspected to be associated with the use of Avastin. |